Why the study?
Does LMWH alone or with GP IIb/IIIa inhibitors improve 30-day survival and reduce in-hospital bleeding compared to UFH alone or with GP IIb/IIIa inhibitors in patients with ACS and varying degrees of renal dysfunction?
Does LMWH alone or with GP IIb/IIIa inhibitors improve 30-day survival and reduce in-hospital bleeding compared to UFH alone or with GP IIb/IIIa inhibitors in patients with ACS and varying degrees of renal dysfunction?
In patients with NSTE-ACS and renal dysfunction, LMWH alone or with GP IIb/IIIa inhibitors is associated with improved 30-day survival and lower bleeding risk compared to UFH.
Answers are grounded in this paper and cite their sources.
LMWH associated with better survival and less bleeding in ACS with renal dysfunction; leaves open need for randomized confirmation.
AIMS: To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status. METHODS AND RESULTS: Patients in the Global Registry of Acute Coronary Events (GRACE) were divided into three groups according to creatinine clearance (CrCl): normal renal function (CrCl >60 mL/min), moderate renal dysfunction (30<CrCl< or =60 mL/min), and severe (CrCl< or =30 mL/min) renal dysfunction. Data were analysed from 11 881 patients with acute coronary syndrome (ACS). Patients with moderate (n=3705) or severe (n=982) renal dysfunction were at higher risk of adverse outcomes than those with normal renal function. Decreasing CrCl was an independent predictor of mortality at 30 days and in-hospital major bleeding. LMWH+GP IIb/IIIa inhibitors were used significantly less frequently in patients with severe (2.0%) or moderate (3.1%) renal dysfunction than in those with normal function (3.9%, P=0.0056). LMWH alone was more beneficial than UFH alone, irrespective of renal status. LMWH alone was an independent predictor of 30 day survival [odds ratio (OR) 0.56; 95% confidence interval (CI) 0.43-0.73] and lower risk of in-hospital bleeding (OR 0.66; 95% CI 0.48-0.92). Bleeding rates were significantly lower with LMWH+GP IIb/IIIa inhibitors than those with UFH+GP IIb/IIIa inhibitors. Use of UFH+GP IIb/IIIa inhibitors was an independent predictor of bleeding (OR 2.02; 95% CI 1.42-2.90) compared with UFH alone. CONCLUSION: In patients with renal dysfunction and non-ST-segment elevation ACS, bleeding complications are more frequent and outcomes appear worse in individuals treated with UFH compared with LMWH. Combination therapy with LMWH and GP IIb/IIIa inhibitors appears to be better tolerated than with UFH and GP IIb/IIIa inhibitors.
No takes yet. Share an insight, caveat, or question.
Collet et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: